TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06465693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unblinded CGM plus nutrition therapy
Description: will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.~will receive Dexcom G6 Pro CGMs to wear throughout the study. The CGM will be unblinded so that the glucose data will be available in real time to the participant and investigators. The dietitian and participant will review CGM data together

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition therapy only
Description: will receive evidence-based nutrition guidance by a certified and licensed registered dietitian (RD), including information on portion sizes, macronutrient types, and effect of carbohydrates on blood glucose.
Study: NCT05793138

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Care Model
Description: First, older adults complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants will continue to receive standard of care. Then after 12 months, they will follow the Geriatric Care Model. They will complete the Geriatric screen for OLder adults receiving Dialysis (GOLD), a battery of validated, self-administered geriatric screening instruments, used to identify Geriatric 5M-related problems. Then, a research team with geriatrics expertise leads patient prioritization of GOLD-identified problems in a telehealth visit and provides the dialysis team with guideline-directed, individualized recommendations for geriatric problem management.
Study: NCT06419192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary advice
Description: Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary advice alone
Description: Advise to eat 7 dates a day from 37SA until delivery. The food will not be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food supplied
Description: Eat 7 dates a day from 37 weeks' gestation until delivery. Women will be provided with the quantity of dates they need.
Study: NCT05915520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: baduinjuin activities
Description: in this 20-geriatric group will receive 5-session per-week 40-minute baduinjuin for 8 weeks plus the daily dose of pantoprazole (40 mg orally administered tablet drug)

Intervention type: OTHER
Group type: OTHER
Intervention: pantoprazole
Description: in this 20-geriatric group will receive the daily dose of pantoprazole (40 mg orally administered tablet drug for 8 weeks .
Study: NCT06150573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Dentifrice
Description: Dentifrice containing 5% weight by weight (w/w) KNO3, 1% alumina, 5% STP and 1150 ppm fluoride as sodium fluoride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Dentifrice (Aquafresh Cavity Protection)
Description: Dentifrice containing 1150 ppm fluoride as sodium fluoride.
Study: NCT05471323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC1012 injection (allo-DNT cells)
Description: RC1012 injection (allo-DNT cells) from healthy donors and have been proved to be safe and demonstrated potent cytotoxicity against AML blasts from AML patients in preclinical and preliminary clinical studies. Allo- DNT cells will be collected from healthy donors (NO MHC match needed) and injected into patients. The drug for this study is an off-the-shelf product. Patients DO NOT need to wait for the cell manufacturing.
Study: NCT06115941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-Op Incentive Spirometer
Description: incentive spirometry group patients were directed to start incentive spirometry, 48 hours prior to surgery. They were given an incentive spirometer and were briefed that they should inhale into the mouth piece of spirometer to lift the balls to the roof of tube and hold for five seconds and then exhale. 13 They were asked to perform 10 such breaths for 6 times in a day till surgery under direct supervision of researcher and this was charted in patient file.
Study: NCT06006663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg.
Description: synthetic intracanal medicament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modified triple antibiotic paste
Description: synthetic intracanal medicament

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: herbal intracanal medicament

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive leaves extract
Description: herbal intracanal medicament
Study: NCT05327556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 0.5 mcg/kg
Description: Syringe with 5 mcg/mL epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine 1 mcg/kg
Description: Syringe with 10 mcg/mL epinephrine
Study: NCT04787094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Stabilization Exercise
Description: Spinal Stabilization Exercise
Study: NCT04749966

Intervention type: OTHER
Intervention: This is an observational study, there are no interventions
Description: This is an observational study, there are no interventions
Study: NCT04539795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat
Description: oral tablet
Study: NCT06271642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only
Description: Participants will have the Bluetooth Haptic Device with experimental Frequency placed on their arm and randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Bluetooth Haptic Device (Control Frequency) + Needle Sham only
Description: Participants will have the Bluetooth Haptic Device with control frequency placed on their arm. They will be randomized to a series of 4 different vibration patterns/frequencies. Mechanical pain threshold (MPT) will be measure using custom-made weighted pinprick stimuli as a set of five pinprick mechanical stimulators with fixed stimulus intensities (flat contact area of 0.2mm diameter) with forces of 32, 64, 128, 256, and 512mN. The stimulators will be applied at a rate of 2s on, 2s off in a randomized order on participants' forearms until the first sensation of pain is reached and will then be done in descending order until the sensation of pain disappears. This procedure will be repeated five times of ascending and descending stimuli served as pinprick pain threshold on 1 arm at 4 different frequencies/patterns in the BHD.
Study: NCT04575142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 laser
Description: the CO2 laser (AcuPulse DUO, Lumenis, Yokneam, Israel) generally ranges from 3 to 10 W in superpulse mode, with 0.05 second on/0.01 second off, depending on lesion size and location of the lesion(s).~The CO2 laser can be used in a continuous, pulsed, or superpulsed mode. The superpulsed mode reduces the exposure time to a few nanoseconds while delivering high energies of 400 to 500 W with each peak. The rest time between each peak allows the tissues to cool and reduces thermal injury to adjacent tissues.
Study: NCT05803434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol oral solution
Description: Cannabidiol will be administered orally twice daily into equally divided doses. The starting dose is 2.5 mg/kg twice daily. The dose can be gradually increased to 5 mg/kg twice daily, which is the recommended maintenance dose, up to a maximum dose of 10 mg/kg twice daily, according to tolerability and clinical response.~Following titration, subjects will continue treatment over a 20-week maintenance period. The total treatment duration from the beginning of the titration period till the end of the maintenance period will be 24 weeks.
Study: NCT03966781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESWL
Description: ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ESWL
Description: In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ERCP
Description: Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
Study: NCT05125289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston technique group
Description: Moist hot pack (10 minutes) Isometric quadriceps exercises (10 repetitions) Straight leg raise (10 repetitions) Graston technique steps 6 long strokes by the GT1 instrument on the hamstring muscle longitudinally. The Graston technique duration will be 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active release technique group
Description: * Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~ART steps:~* Subject lies on the plinth in prone or in side lying position with the dominant side facing upwards.~* Gentle tension is applied to the hamstring muscle along the entire length while stretching the leg in prone lying or side lying positions, depending on the level of pain and tightness of muscle (5 repetitions at 5 seconds interval).~* Gentle tension is also applied at the origin and insertion of the hamstring muscle until the patient feels full release.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation stretching group
Description: * Moist hot pack (10 minutes)~* Isometric quadriceps exercises (10 repetitions)~* Straight leg raise (10 repetitions)~PNF technique steps:~* The subject is in supine position with his non-dominant leg strapped down the table while the dominant leg rests on the therapist right shoulder.~* The therapist stretches the hamstring muscle until the subject first reports a mild stretch sensation; held for 7 sec by passively flexing the hip with knee fully extended, allowing no hip rotation.~* Next, the subject isometrically contracts the hamstring muscle for 3 sec and then relax for 5 sec.~* This sequence is repeated 5 times at a 20 second interval.
Study: NCT06417918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tuko Pamoja, We are Together in Kiswahili
Description: Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context.
Study: NCT04766476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-963272
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-963272
Description: Specified dose on specified days
Study: NCT05850754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vantage Hemp CBD
Description: Participants will consume 1 Vantage Hemp capsule, daily for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vantage Hemp Placebo Capsule
Description: Vantage Hemp Placebo Capsule Intervention
Study: NCT04275141

Intervention type: OTHER
Group type: OTHER
Intervention: oral glucose load
Description: oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min

Intervention type: OTHER
Group type: OTHER
Intervention: oral glucose load
Description: oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min

Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min

Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: oral glucose load (60g) followed by exercise at fixed wattage (60W) for 30 min
Study: NCT06062745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: 18F-fluciclovine is a radiotracer targeting amino-acid transporters.Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance to make images of processes that are happening in the body

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
Study: NCT04539795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat
Description: oral tablet
Study: NCT05168748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMJ995 single agent
Description: Single intravenous administration of IMJ995
Study: NCT06474975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AURA 10 PET/CT
Description: The PET/CT specimen imager (AURA 10 PET/CT) is used to intraoperatively assess resection margins and histopathological findings of the breast tumor specimen are applied as the gold standard
Study: NCT05927922

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Ibuprofen (Abbott, Egypt)
Description: ibuprofen is analegisic drug used to relieve pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Ibuprofen (Abbott, Egypt)
Description: ibuprofen is analegisic drug used to relieve pain
Study: NCT04557085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets
Study: NCT05425069

Intervention type: DRUG
Intervention: Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P
Description: We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)

Intervention type: DRUG
Intervention: Comparison MoCA test and EEG connectivity pre, intra and postoperative between groups P vs D-P
Description: We compare de impact in EEG, anesthetic condition, and recovery EEG and cognitive clinical characteristic with MoCA test between both groups (propofol vs propofol dexmedetomidine)
Study: NCT05740033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split-Thickness Skin Graft for Radial Forearm Donor Site Closure
Description: This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hatchet Flap for Radial Forearm Donor Site Closure
Description: The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.
Study: NCT06502106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condensed Internet delivered prolonged exposure (CIPE)
Description: Condensed Internet delivered prolonged exposure (CIPE) with therapist support for three weeks.
Study: NCT06393582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuracy of full-arch implant impressions
Description: Conventional impressions for full-arch implant impressions will be digitized and used as a reference for comparison.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accuracy of full-arch implant impressions using intraoral scanners
Description: Digital scanners impressions for full-arch implant impressions will be compared to the reference (conventional) impressions
Study: NCT05551767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-FU 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg)
Study: NCT06460233

Intervention type: PROCEDURE
Intervention: Bariatric surgery - sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy performed according to the current surgical standards
Study: NCT04568759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global postural re-education
Description: GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global postural re-education
Description: GPR consists of active treatment posture and sensorimotor control exercises to regain back muscle symmetry and correct posture in daily activities
Study: NCT04938830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clesrovimab
Description: IM injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM injection
Study: NCT05690282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Pain Management (Ibuprofen/Acetaminophen/GABAPentin/0.25%Bupivacaine)
Description: Multimodal Pain Management to minimize patients' reliance on opioids.
Study: NCT05615051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface decontamination procedure aiming at reconstructive therapy
Description: Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surface decontamination procedure aiming at reconstructive therapy
Description: Surface decontamination of infected implants followed by reconstructive therapy to manage peri-implantitis
Study: NCT06257771

Intervention type: DRUG
Intervention: Alcohol (Ethanol)
Description: Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.

Intervention type: DRUG
Intervention: Alcohol (Ethanol)
Description: Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.

Intervention type: DRUG
Intervention: Alcohol (Ethanol)
Description: Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.

Intervention type: DRUG
Intervention: Alcohol (Ethanol)
Description: Alcohol given orally (0.5 grams of alcohol per kg of fat-free mass) Alcohol given iv with a clamp ( 6% v/v alcohol prepared in 0.5% normal saline). The infusion rate will exponentially increase from the start of the infusion until the target BrAC of 0.6g/L (60mg%) is reached at 15 min, followed by an exponentially decreasing infusion rate, which will be tapered to a constant steady-state value to clamp the BrAC at the target value for a predetermined duration of 180 min.